Role of hydroxychloroquine in preconception period of recurrent miscarriage patients

Mamta Singh

doi:10.18203/2320-1770.ijrcog20230690

Authors

Mamta Singh Sparsh Hospital, Nasrapur, Tirwa Road, Kannauj, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20230690

Keywords:

Recurrent pregnancy loss, Immune systems, Immunomodulatory drugs, Hydroxychloroquine, Preconception period

Abstract

Background: Three or more times of embryonic or fetal losses is termed as recurrent pregnancy loss (RPL). 1-2% women globally suffer from RPL which in turn causes physical and emotional devastation in such women. A deregulation of immune cells and cytokines is observed in women with RPL. Immunomodulatory drugs like hydroxychloroquine (HCQ) could thus be a justifiable line of therapy for normal conceiving in women who encountered RPL. Thus, the objective of current study was to evaluate whether oral administration of HCQ 200 mg twice a day in preconception period would improve conception and pregnancy outcome in RPL patients or not.

Methods: Total 50 women with history of RPL and difficulty in conception were given 200 mg bd of HCQ orally twice a day along with once a day 5 mg dose of folic acid. To the above treatment protocol low dose ecosprin was added immediately after positive pregnancy test. After 20 weeks, HCQ dose was terminated while ecosprin was continued. Iron, calcium and protein supplements were continued in all patients.

Results: 36 patients out of 50 who received HCQ conceived easily. Majority of patients who received the treatment protocol remained asymptomatic and exhibited no severe adverse effects. Out of 36 patients who conceived total 15 patients had normal delivery while 8 patients underwent lower segment caesarean section (LSCS) at term end and 5 patients had to undergo preterm delivery.

Conclusions: HCQS use in preconception period facilitate conception and prevent miscarriage in refractory cases of RPL.

Metrics

Metrics Loading ...

References

Miscarriage. Available at: https://www.who.int/news-room/spotlight/why-we-need-to-talk-about-losing-a-baby. Accessed on 20 November 2022.

Dimitriadis E, Menkhorst E, Saito S, Kutteh WH, Brosens JJ. Recurrent pregnancy loss. Nat Rev Dis Primers. 2020;6(1):98.

Rasmark Roepke E, Matthiesen L, Rylance R, Christiansen OB. Is the incidence of recurrent pregnancy loss increasing? A retrospective register-based study in Sweden. Acta Obstet Gynecol Scand. 2017;96(11):1365-72.

Kaiser J, Branch DW. Recurrent Pregnancy Loss: Generally Accepted Causes and Their Management. Clin Obstet Gynecol. 2016;59(3):464-73.

El Hachem H, Crepaux V, May-Panloup P, Descamps P, Legendre G, Bouet PE. Recurrent pregnancy loss: current perspectives. Int J Womens Health. 2017;9:331-45.

Lessey BA. The role of the endometrium during embryo implantation. Hum Reprod. 2000;15(6):39-50.

Kniotek M, Zych M, Roszczyk A, Szafarowska M, Jerzak MM. Decreased Production of TNF-α and IL-6 inflammatory cytokines in non-pregnant idiopathic rpl women immunomodulatory effect of sildenafil citrate on the cellular response of idiopathic RPL Women. J Clin Med. 2021;10(14):3115.

Lee SK, Na BJ, Kim JY, Hur SE, Lee M, Gilman-Sachs A, Kwak-Kim J. Determination of clinical cellular immune markers in women with recurrent pregnancy loss. Am J Reprod Immunol. 2013;70(5):398-411.

Nakashima A, Shima T, Inada K, Ito M, Saito S. The balance of the immune system between T cells and NK cells in miscarriage. Am J Reprod Immunol. 2012;67(4):304-10.

Chakrabarti K, McCune WJ. Advances in the clinical use of hydroxychloroquine levels. Curr Opin Rheumatol. 2022;34(3):151-7.

Huybrechts KF, Bateman BT, Zhu Y, Straub L, Mogun H, Kim SC, Desai RJ, Hernandez-Diaz S. Hydroxychloroquine early in pregnancy and risk of birth defects. Am J Obstet Gynecol. 2021;224(3):e1-22.

Pasquier E, de Saint-Martin L, Marhic G, Chauleur C, Bohec C, Bretelle F, et al. Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study. BMJ Open. 2019;9(3):e025649.

de Moreuil C, Alavi Z, Pasquier E. Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage. Br J Clin Pharmacol. 2020;86(1):39-49.

Mekinian A, Vicaut E, Cohen J, Bornes M, Kayem G, Fain O. Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL. Gynecol Obstet Fertil Senol. 2018;46(7-8):598-604.